| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Incubation of bovine parathyroid cells with 1,25-dihydroxyvitamin D3 (1,25-(OH)2D3) decreased both preproparathyroid mRNA levels and parathyroid hormone (PTH) secretion. There was a fall to 56·6 ± 13·7% (mean ± S.E.M.) and 65·1 ± 9·3% in mRNA levels and PTH secretion respectively at 1 nmol 1,25-(OH)2D3/l, and 41·1 ± 13·6% and 42·0 ± 12·1% at 10 nmol 1,25-(OH)2D3/l after 24 h. After 48 h in 0·1 nmol 1,25-(OH)2D3/l, mRNA levels had fallen to 35·3 ± 12·6% and PTH secretion to 32·1 ± 5·0%. In human adenomatous cells, however, incubation with 1,25-(OH)2D3 (10 nmol/l) had no effect on either mRNA levels or PTH secretion even after 48 h. This lack of sensitivity of adenomatous cells to 1,25-(OH)2D3 was not due to an absence of receptors (3847 ± 39 receptors/ng cytosolic protein in adenomatous cells compared with 4068 ± 371 in bovine cells) or receptors being of low affinity.
Cortisol (1 µmol/l) caused a reduction in the number of receptors for 1,25-(OH)2D3 in bovine parathyroid cells of approximately 20% within 24 h of incubation, but no change in affinity. This decrease was accompanied by abolition of the response to 1,25-(OH)2D3 and was reversible, in that withdrawal of cortisol for the final 24 h of incubation was sufficient for the response to return, the number of receptors having returned to control values.
These results suggest that only a small percentage of receptors for 1,25-(OH)2D3 in bovine parathyroid cells may be functional at any one time. Furthermore, the insensitivity of human adenomatous cells to 1,25-(OH)2D3 does not seem to be due to a lack of receptors but may be due to a defect in the interaction between the receptor protein and the PTH gene.
Journal of Endocrinology (1989) 123, 137–142
This article has been cited by other articles:
|
|
 |
|
  T. Carling, J. Rastad, E. Szabó, G. Westin, and G. Åkerström Reduced Parathyroid Vitamin D Receptor Messenger Ribonucleic Acid Levels in Primary and Secondary Hyperparathyroidism J. Clin. Endocrinol. Metab., May 1, 2000; 85(5): 2000 - 2003. [Abstract] [Full Text]
|
|
|
|
|
|
P. Correa, J. Rastad, P. Schwarz, G. Westin, A. Kindmark, E. Lundgren, G. Åkerström, and T. Carling The Vitamin D Receptor (VDR) Start Codon Polymorphism in Primary Hyperparathyroidism and Parathyroid VDR Messenger Ribonucleic Acid Levels J. Clin. Endocrinol. Metab., May 1, 1999; 84(5): 1690 - 1694. [Abstract] [Full Text]
|
|
|
|
 |
|
 Y. C. Li, M. Amling, A. E. Pirro, M. Priemel, J. Meuse, R. Baron, G. Delling, and M. B. Demay Normalization of Mineral Ion Homeostasis by Dietary Means Prevents Hyperparathyroidism, Rickets, and Osteomalacia, But Not Alopecia in Vitamin D Receptor-Ablated Mice Endocrinology, October 1, 1998; 139(10): 4391 - 4396. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Carling, J. Rastad, G. Åkerström, and G. Westin Vitamin D Receptor (VDR) and Parathyroid Hormone Messenger Ribonucleic Acid Levels Correspond to Polymorphic VDR Alleles in Human Parathyroid Tumors J. Clin. Endocrinol. Metab., July 1, 1998; 83(7): 2255 - 2259. [Abstract] [Full Text]
|
|
|
|
|
|
T. Carling, P. Ridefelt, P. Hellman, J. Rastad, and G. Akerstrom Vitamin D Receptor Polymorphisms Correlate to Parathyroid Cell Function in Primary Hyperparathyroidism J. Clin. Endocrinol. Metab., June 1, 1997; 82(6): 1772 - 1775. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
